Nanoform Finland Oyj Stock Nasdaq Helsinki
Equities
FI4000330972
Biotechnology & Medical Research
Sales 2024 * | 7.48M 8.12M 11.08M | Sales 2025 * | 14.6M 15.85M 21.6M | Capitalization | 164M 178M 243M |
---|---|---|---|---|---|
Net income 2024 * | -15M -16.28M -22.2M | Net income 2025 * | -11M -11.94M -16.28M | EV / Sales 2024 * | 16.8 x |
Net cash position 2024 * | 38.32M 41.6M 56.7M | Net cash position 2025 * | 28.65M 31.1M 42.39M | EV / Sales 2025 * | 9.3 x |
P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-13.7
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.79% |
Latest transcript on Nanoform Finland Oyj
Managers | Title | Age | Since |
---|---|---|---|
Edward Hæggström
CEO | Chief Executive Officer | 55 | 14-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
Investor Relations Contact | - | 19-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 68 | 19-04-01 | |
Mads Laustsen
BRD | Director/Board Member | 67 | 18-12-31 |
Albert Häggström
DFI | Director of Finance/CFO | 53 | 14-12-31 |
1st Jan change | Capi. | |
---|---|---|
+44.48% | 54.04B | |
+43.57% | 41.96B | |
-0.86% | 41.92B | |
-7.59% | 28.35B | |
+12.30% | 26.35B | |
-21.83% | 19B | |
+7.15% | 13B | |
+29.40% | 12.28B | |
+25.15% | 12.19B |